Merck (MRK) Tops Q3 EPS by 4c; Lifts FY15 EPS Outlook
- Wall St stocks end higher with major corporate earnings in view
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Cadence (CDNS) tumbles despite Q1 beat on top and bottom lines
- Tesla expands price cuts to China, Germany after reducing FSD cost; shares down
- Gold prices slide as M.East fears ease, rate jitters persist
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
Leerink Partners Reiterates Market Perform on Merck (MRK) Following 3Q EPS Beat
October 28, 2015 9:31 AM EDTLeerink Partners reiterated a Market Perform rating and $67.00 price target on Merck (NYSE: MRK) following the company's 3Q earnings results. MRK reported a $0.04 EPS beat. US sales of Januvia/Janumet increased by 22%, but was benefited by ~$100M due to the timing of consumer buying that is expected to negatively impact future quarters.
Analyst Seamus Fernandez... More